Trial Profile
A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Iadademstat (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Acronyms CLEPSIDRA
- Sponsors Oryzon
- 07 Jul 2023 Last checked against European Clinical Trials Database record.
- 07 Jul 2023 Status changed from recruiting to completed.
- 21 Sep 2020 Results (n=14) presented at the 45th European Society for Medical Oncology Congress